Today it was reported that the Sr. V.P., Research & CSO of Xencor Inc (NASDAQ: XNCR), John Desjarlais, exercised options to sell 35,000 XNCR shares at $4.25 a share, for a total transaction value of $1.41M.
Following John Desjarlais’ last XNCR Sell transaction on August 24, 2016, the stock climbed by 18.5%. In addition to John Desjarlais, 2 other XNCR executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Xencor Inc has an average volume of 183.2K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $51.00, reflecting a -21.3% downside.
The insider sentiment on Xencor Inc has been negative according to 23 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions.
